This study is planned to explore the effect of food on the oral pharmacokinetics, the intravenous pharmacokinetics and the absolute bioavailability of BAY1834845. Furthermore, this study will investigate the effect of BAY1834845 on the pharmacokinetics of orally administered methotrexate in healthy male subjects.
- Male; healthy according to complete medical history, physical examination, vital signs, 12-lead ECG and clinical laboratory tests as listed in the exclusion criteria given below. - Age 18–50 years (inclusive) at the first screening visit. - Body mass index: >=18 kg/m² and <=30 kg/m². - Sexually active men must agree to practice adequate methods of contraception (protection). This applies for the time period between signing of the informed consent form and up to 90 days after the last administration of the study drug(s).
- Any contraindications for intake of BAY 1834845 or methotrexate, gastrointestinal, liver, renal, lung or cardiovascular disorders, malignant tumors, known severe allergies, known or suspected immunodeficiency - Medication history: drugs known to induce/inhibit liver enzymes - Smoking - Clinically relevant findings in -- physical -- ECG, blood pressure -- laboratory values - Known hypersensitivity to study drug(s)
GRONINGEN, Netherlands, 9728 NZ
E-mail: [email protected]
Phone: (+) 1-888-8422937
Open label, randomized, cross-over study to explore the pharmacokinetics of BAY1834845 after oral and intravenous dosing, including food effect and absolute bioavailability (Part A), and to investigate the effect of BAY1834845 on the pharmacokinetics of orally administered methotrexate (Part B) in healthy male subjects